Skip to content

Berman Center for Outcomes & Clinical Research

Better Care through Better Research

Since its inception in 1965, the Berman Center for Outcomes & Clinical Research has been a leader in cardiovascular research and a clinical site for over 100 trials areas such as

  • heart and kidney disease
  • diabetes
  • women’s health
  • cancer
  • neurological disorders

For several of these trials, the Berman Center initiated the investigation and was responsible for study design, implementation, and analysis. The Berman Center for Outcomes & Clinical Research is a division of Hennepin Healthcare Research Institute (HHRI), formerly known as Minneapolis Medical Research Foundation (MMRF), which is a subsidiary of Hennepin Healthcare System, Inc.

Hennepin Healthcare is an integrated system of care that includes HCMC, a nationally recognized Level 1 Trauma Center, medical research and teaching hospital located in downtown Minneapolis.

The Berman Center is compliant with Good Clinical Practice (GCP) and/or regulatory requirements consistent with “best practices” guidelines and focuses on outcomes to impact health policy and practice.

As was the intent of founder Dr. Reuben Berman, a pioneer in the field of cardiovascular clinical research, our primary mission is to empower the medical community to offer better patient care through better research.

Our Investigators

Anne Murray, MD, MSc
Addiction Medicine - Gavin Bart, MD, PhD
Food Insecurities - Dianna Cutts, MD
Richard Grimm, Jr., MD, PhD - Emeritus

Active Studies

grampa with kids for ASPREE study
ASPirin in Reducing Events in the Elderly (ASPREE)
ASPREE is the largest international trial ever funded by the US National Institute on Aging (NIA), enrolling 19,000 participants age 65 or older in the US and Australia, randomizing them to either daily low dose aspirin or placebo.  This study will help answer questions as to whether or not daily aspirin use for…
eldely couple for Kidney study
Chronic Kidney Disease
If you are interested or would like more information about BRINK, please call (612) 341-7904 or email info@bermancenter.org. The BRain In Kidney Disease Study (BRINK) The goal of this study is to learn how common memory problems are in patients with and without chronic kidney disease (CKD), and the possible causes of these…
image of MRI brain scans
Northstar: Addiction Medicine Clinical Research
Substance Abuse Research The Northstar Node is member of the National Drug Abuse Treatment Clinical Trials Network (CTN), a means by which medical and specialty treatment providers, treatment researchers, participating patients, and the National Institute on Drug Abuse cooperatively develop, validate, refine, and deliver new treatment options to patients. This unique partnership enables…

Volunteer

Join a research study, help others, and learn more about your own health.  Please browse through the sidebar to see which of our enrolling studies interests you.

For more information on any of our current studies, please call 612-873-6900 or email info@bermancenter.org.

Previous Studies

Our Collaborators

Principal Investigators for multi-site trials for which the Berman Center has served either as a regional coordinator or as a clinical site:

Colin B, Baignet, BM * University of Oxford, Oxford, United Kingdom * SHARP, Study of Heart and Renal Protection

Merit Cudkowicz, MD * Massachusetts General Hospital/Harvard Medical School, Boston, MA * Celebrex in ALS

Robert Byington, PhD * Wake Forest School of Medicine, Winston-Salem, NC * ACCORD, Action to Control Cardiovascular Risks in Diabetes

John McNeil, PhD, MSc * Monash University, Melbourne, Australia * ASPREE, ASPirin in Reducing Events in the Elderly

Charles H. Hennekens, MD, DrPh * Mount Sinai Medical Center * TACT, Trial to Assess Chelation Therapy (Co-principal Investigator)

Gervasio A. Lamas, MD * Mount Sinai Medical Center * TACT, Trial to Assess Chelation Therapy (Co-principal Investigator)

Oscar Benavente, MD * University of Texas Health Science Center, San Antonio, TX *
SPS3, Secondary Prevention of Small Subcortical Strokes

Martin Landray, BM * University of Oxford, Oxford, United Kingdom * SHARP, Study of Heart and Renal Protection

Jeffery Probstfield, MD * University of Washington School of Medicine * ORIGIN, Outcome Reduction with Initial Glargine Intervention (Principal Investigator for U.S. Regional Coordinating Center)

Eric Sorenson, MD * Mayo Clinic, Rochester, MN * IGF-I (Myotrophin) in ALS

Hertzel Gerstein, MD * Professor of Medicine and Chief of Division of Endocrinology
McMaster University Faculty of Health Sciences
Hamilton, Ontario, Canada * ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator) * DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (Co-principal Investigator)

Salim Yusuf, MD * Professor of Medicine and Chief of Division of Cardiology
McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator)
DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone
Medication (Co-principal Investigator) * ONTARGET/TRANSCEND
OnTarget: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial: A large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events Transcend: Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease

The Berman Center has established high-quality, primary and specialty care research networks that extend across the globe. The networks include cardiologists, neurologists, endocrinologists, nephrologists, hypertension specialists and internists covering a wide range of chronic disease disciplines. Additionally, these networks include many experienced clinical research associates trained in ICH-GCP procedures. The networks include centers in established markets such as North America, Western Europe and Australia. Utilizing in-depth feasibility studies, Berman can quickly identify appropriate sites that have a commitment to scientific excellence, have a history of delivery to timelines, and quality of operations.

Contact

info@bermancenter.org

612-873-6900

Mailing Address:
701 Park Ave, PP4.440
Minneapolis MN 55415

Physical Address:
825 S 8th St, Suite 440
Minneapolis MN 55404

input search string and hit enter